Vicore Pharma Completes ASPIRE Trial Enrollment in IPF
Stockholm, Sweden – April 22, 2026 In a significant advancement for respiratory therapeutics, Vicore Pharma has announced the successful...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Stockholm, Sweden – April 22, 2026 In a significant advancement for respiratory therapeutics, Vicore Pharma has announced the successful...
Stockholm, Sweden, December 19, 2025 — Vicore Pharma Holding AB (publ) announced that it will move from the Nasdaq...
